טוען...

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE

INTRODUCTION: We report safety and efficacy in patients treated with dimethyl fumarate (DMF) for ~9 years in ENDORSE. Lymphocyte analysis data are also reported. METHODS: Incidence of serious adverse events (SAEs), discontinuations due to adverse events (AEs), annualized relapse rate (ARR) and Expan...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Ther Adv Neurol Disord
Main Authors: Gold, Ralf, Arnold, Douglas L., Bar-Or, Amit, Fox, Robert J., Kappos, Ludwig, Chen, Chongshu, Parks, Becky, Miller, Catherine
פורמט: Artigo
שפה:Inglês
יצא לאור: SAGE Publications 2020
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7222239/
https://ncbi.nlm.nih.gov/pubmed/32426039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420915005
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!